Blurbs

JonesTrading Sticks to Its Buy Rating for Chimerix (CMRX)

In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Chimerix (CMRXResearch Report), with a price target of $14.00. The company’s shares closed last Tuesday at $5.62, close to its 52-week low of $4.75.

According to TipRanks.com, Roy is a 4-star analyst with an average return of 12.1% and a 32.0% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Actinium Pharmaceuticals, and Monopar Therapeutics Inc.

Currently, the analyst consensus on Chimerix is a Strong Buy with an average price target of $20.00, representing a 247.8% upside. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $24.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $10.89 and a one-year low of $4.75. Currently, Chimerix has an average volume of 880.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.

Read More on CMRX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos